Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3560-3568

  André, Thierry ^a   Bensmaine, Mohamed A ^a   Louvet, Christophe ^a   François, Eric ^a   Lucas, Virginie ^a   Desseigne, Françoise ^a   Beerblock, Karine ^a   Bouché, Olivier ^a   Carola, Elisabeth ^a   Merrouche, Yacine ^a   Morvan, François ^a   Dupont André, Ghislaine ^a   De Gramont, Aimery ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032730143     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3560     Document Type: Article

References (25)

1. Menegoz F, Black RJ, Arveux P, et al: Cancer incidence and mortality in France in 1975-1995. Eur J Cancer Prev 6:442-446, 1997
2. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
3. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
4. Beerblock K, Rinaldi Y, André T, et al: Bimonthly high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in advanced colorectal cancer. Cancer 79:1100-1105, 1997
5. Pitot HC, Wender DB, O'Connell MJ, et al: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910-2919, 1997
6. Rougier P, Bugat R, Douillard JY, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
7. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
8. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
9. Raymond E, Buquet-Fagot C, Djelloul S, et al: Antitumor activity of oxaliplatin in combination with fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anti-Cancer Drugs 8:876-885, 1997
10. Raymond E, Faivre S, Woynarowski JM, et al: Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 25:4-12, 1998 (suppl 5)
11. Raymond E, Chaney SG, Taamma A, et al: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 9:1053-1071, 1998
12. Levi F, Perpoint B, Garufi C, et al: Oxaliplatin activity against metastatic colorectal cancer: A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29:1280-1284, 1993
13. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95-98, 1996
14. Bécouarn Y, Ychou M, Ducreux M, et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer. J Clin Oncol 16:2739-2744, 1998
15. Díaz-Rubio E, Sastre J, Zaniboni A, et al: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 9:105-108, 1998
16. André T, Louvet C, Raymond E, et al: Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 9:1251-1253, 1998
17. Garufi C, Brienza S, Bensmaine MA, et al: Addition of oxaliplatin (L-OHP) to chronomodulated (CM) 5-fluorouracil (5FU) and folinic acid (FA) for reversal of acquired chemoresistance in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 14:192, 1995 (abstr 446)
18. Gamelin E, Meyer V, Delva R, et al: Oxaliplatin and 5-fluorouracil synergism in pretreated advanced colorectal patients. Proc Am Soc Clin Oncol 16:310a, 1997 (abstr 1102.5)
19. Berteault-Cvitkovic F, Jami A, Itzakhi M, et al: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 14:2950-2958, 1996
20. de Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pre-treated metastatic colorectal cancer. Eur J Cancer 33:214-219, 1997
21. Levi F, Misset JL, Brienza S, et al: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump: High antitumor effectiveness against metastatic colorectal cancer. Cancer 69:893-900, 1992
22. MacDonald J, Haller D, Mayer R: Grading of toxicity, in MacDonald J, Haller D, Mayer R (eds): Manual of Oncologic Therapeutics. Philadelphia, PA, Lippincott, 1995, pp 519-523
23. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. de Gramont A, Figer A, Seymour M, et al: A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 17:257a. 1998 (abstr 985)